

# MEN-Study: A randomized cross-over study on the effects of the skin patch and the vaginal ring versus a levonorgestrel containing oral contraceptive on the anticoagulations pathways

<b>Submission date</b> 27/01/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 27/01/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 19/08/2009	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Bea Hiemstra

**Contact details**  
Leiden University Medical Center Department of Gynaecology  
P.O. Box 9600  
Leiden  
Netherlands  
2300 RC  
+31 (0)71 5262871  
B.Hiemstra@lumc.nl

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

## **Scientific Title**

### **Acronym**

MEN-Study (Microgynon 30-EVRA-Nuvaring Study)

### **Study objectives**

The effect on Activated Protein C (APC)-resistance of the skin patch and the vaginal ring contraceptives, containing third generation gestagens, is significantly increased in comparison with oral contraceptives, containing second generation gestagens.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Received from local medical ethics committee

### **Study design**

Randomised open label active controlled crossover group trial

### **Primary study design**

Interventional

### **Study type(s)**

Other

### **Health condition(s) or problem(s) studied**

Femal contraception, healthy person

### **Interventions**

Skin patch and the vaginal ring versus a levonorgestrel containing oral contraceptive

### **Intervention Type**

Other

### **Phase**

Not Specified

### **Primary outcome(s)**

APC-resistance

### **Key secondary outcome(s))**

Other coagulation factors

### **Completion date**

31/12/2006

## **Eligibility**

### **Key inclusion criteria**

Healthy female volunteers from 18-45 years

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

45 years

**Sex**

Female

**Key exclusion criteria**

1. Underage
2. Contra-indication for use of the contraceptive ring, skin patch or oral contraceptives, as termed by World Health Organization (WHO), Northern Virginia Oncology Group (NVOG) and the Dutch General Practitioners Society (Nederlands Huisartsen Genootschap [NHG])
3. Use of hormonal contraception or hormonal substitution therapy 2 months before inclusion
4. Pregnancy 3 months before inclusion or during the study
5. Use of medication with effect on the blood coagulation
6. Chronic or acute diseases
7. Lupus anticoagulans

**Date of first enrolment**

01/01/2005

**Date of final enrolment**

31/12/2006

**Locations**

**Countries of recruitment**

Netherlands

**Study participating centre**

**Leiden University Medical Center Department of Gynaecology**

Leiden

Netherlands

2300 RC

# Sponsor information

## Organisation

Leiden University Medical Centre (LUMC) (Netherlands)

## ROR

<https://ror.org/027bh9e22>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Leiden University Medical Centre (LUMC), Department of Gynaecology (Netherlands)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2009		Yes	No